Ligand Pharmaceuticals, Inc. (LGND)
299.00
+5.19
(+1.77%)
USD |
NASDAQ |
Nov 18, 16:00
299.00
0.00 (0.00%)
After-Hours: 20:00
Ligand Pharmaceuticals EPS Diluted (Quarterly) : -1.427 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -1.427 |
| June 30, 2026 | 2.221 |
| March 31, 2026 | -0.6712 |
| December 31, 2025 | 2.119 |
| September 30, 2025 | 5.685 |
| June 30, 2025 | 0.2432 |
| March 31, 2025 | -2.212 |
| December 31, 2024 | -1.638 |
| September 30, 2024 | -0.3894 |
| June 30, 2024 | -2.880 |
| March 31, 2024 | 4.753 |
| December 31, 2023 | 1.029 |
| September 30, 2023 | -0.5911 |
| June 30, 2023 | 0.1292 |
| March 31, 2023 | 2.334 |
| December 31, 2022 | -1.035 |
| September 30, 2022 | 0.0236 |
| June 30, 2022 | -0.0531 |
| March 31, 2022 | -0.9145 |
| December 31, 2021 | -0.3237 |
| September 30, 2021 | 0.8006 |
| June 30, 2021 | 1.789 |
| March 31, 2021 | 1.050 |
| December 31, 2020 | 0.3453 |
| September 30, 2020 | -0.4167 |
| Date | Value |
|---|---|
| June 30, 2020 | 1.323 |
| March 31, 2020 | -1.460 |
| December 31, 2019 | -0.4271 |
| September 30, 2019 | -0.8125 |
| June 30, 2019 | -0.7372 |
| March 31, 2019 | 31.32 |
| December 31, 2018 | -2.016 |
| September 30, 2018 | 2.801 |
| June 30, 2018 | 2.99 |
| March 31, 2018 | 1.83 |
| December 31, 2017 | -0.3321 |
| September 30, 2017 | 0.3578 |
| June 30, 2017 | 0.26 |
| March 31, 2017 | 0.2206 |
| December 31, 2016 | -0.1496 |
| September 30, 2016 | 0.0457 |
| June 30, 2016 | -0.2962 |
| March 31, 2016 | 0.2637 |
| December 31, 2015 | 0.29 |
| September 30, 2015 | 9.281 |
| June 30, 2015 | 1.11 |
| March 31, 2015 | 0.04 |
| December 31, 2014 | 0.34 |
| September 30, 2014 | 0.06 |
| June 30, 2014 | 0.07 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Johnson & Johnson | 0.0858 |
| Eli Lilly & Co. | 7.221 |
| Bristol Myers Squibb Co. | 1.053 |
| Xeris Biopharma Holdings, Inc. | 0.0594 |
| LENZ Therapeutics, Inc. | -0.9856 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -28.48M |
| Revenue (Quarterly) | 78.75M |
| Total Expenses (Quarterly) | 107.23M |
| Enterprise Value | 6.579B |
| Gross Profit Margin (Quarterly) | 83.68% |
| Profit Margin (Quarterly) | -36.17% |
| Earnings Yield | 0.75% |
| Operating Earnings Yield | 0.59% |
| Normalized Earnings Yield | 1.239 |